Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

COPD Foundation and DevPro Biopharma Join Forces to Develop Treatments for People with COPD and Related Lung Conditions Miami, FL, and Basking Ridge, NJ , March 23, 2021 (GLOBE NEWSWIRE) -- The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma LLC, a clinical research and development company,...

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) --  Arch...

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....

Topout Provides Global-Leading Oxygen Delivery Systems -Ingen Makes Head-way in the UK and Europe- --Topout Oxygeneering Ltd: Leading Provider, High Altitude Oxygen Delivery System—Ingen's Oxyview Technology: Oxyview Climbs Mt. Everest:...